|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3-4
|
|
pubmed:dateCreated |
1996-3-19
|
|
pubmed:abstractText |
The role of surgery as initial treatment in gastric lymphoma remains controversial. We have prospectively evaluated a stomach conservation strategy in histologically aggressive gastric lymphoma, using primary adriamycin-containing chemotherapy, followed by involved-field radiotherapy in patients with limited disease. Twenty-six patients (median age 69 years) were entered in this study; 15 had stage I disease, 7 had stage II disease and 4 had stage IV disease. The chemotherapy combinations were CHOP (18 patients) and ProMACE/MOPP (8 patients). Radiotherapy was given to 11 patients. Of the 24 patients evaluated for response, 18 (75%) achieved endoscopically-confirmed complete response and 4 (17%) partial response. During follow-up (median 22 months), none of the complete responders developed recurrent lymphoma. Gastric resection was performed in 1/26 patients who did not respond to primary chemotherapy. There were no cases of perforation, but three patients (12%) developed acute gastro-intestinal bleeding a few days after the onset of chemotherapy, one of whom required a surgical devascularization procedure. There was no treatment-related mortality. These data further support the non-surgical approach in histologically aggressive gastric lymphoma, using primary chemotherapy with or without radiation therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1042-8194
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
321-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8580802-Adult,
pubmed-meshheading:8580802-Aged,
pubmed-meshheading:8580802-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8580802-Cyclophosphamide,
pubmed-meshheading:8580802-Disease Progression,
pubmed-meshheading:8580802-Doxorubicin,
pubmed-meshheading:8580802-Drug Administration Schedule,
pubmed-meshheading:8580802-Etoposide,
pubmed-meshheading:8580802-Female,
pubmed-meshheading:8580802-Gastrointestinal Hemorrhage,
pubmed-meshheading:8580802-Humans,
pubmed-meshheading:8580802-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8580802-Male,
pubmed-meshheading:8580802-Mechlorethamine,
pubmed-meshheading:8580802-Methotrexate,
pubmed-meshheading:8580802-Middle Aged,
pubmed-meshheading:8580802-Neoplasm Staging,
pubmed-meshheading:8580802-Prednisone,
pubmed-meshheading:8580802-Procarbazine,
pubmed-meshheading:8580802-Prospective Studies,
pubmed-meshheading:8580802-Radiotherapy, Adjuvant,
pubmed-meshheading:8580802-Stomach Neoplasms,
pubmed-meshheading:8580802-Vincristine
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
|
|
pubmed:affiliation |
Department of Oncology, Rambam Medical Center, Haifa, Israel.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
